First-in-class drug for chronic cough shows efficacy

AusDoc brings you the latest news from the European Respiratory Society Congress 2020.
Gefapixant, a first-in-class P2X3 receptor antagonist, is efficacious for chronic cough but only at the higher of two doses tested, trial results show.
Results of two parallel randomised industry-funded placebo-controlled trials, COUGH-1 and COUGH-2, including more than 2000 patients, were presented as at the European Respiratory Society’s 2020 (ERS 2020) virtual international congress this week.
All participants (75% female, 79% Caucasian) had suffered chronic cough that was unexplained or refractory for at least a year (mean duration was over a decade) without substantial abnormalities on chest X-ray.